With a 90% response rate and median progression-free survival approaching four years, taletrectinib is now the preferred frontline treatment for ROS1-positive NSCLC. Its efficacy and manageable safety profile, primarily transient GI toxicity and manageable LFT elevation, surpass older-generation inhibitors.

With multiple ADCs available, an emerging sequencing strategy is to alternate between different mechanisms of action, such as following a microtubule toxin-based ADC with a topoisomerase-1 inhibitor payload. This approach aims to avoid compounding specific toxicities, like neuropathy, and potentially circumvent resistance, though it is a strategy born from logic rather than clinical trial data.

While ALK and ROS1 are similar kinases, assuming cross-activity of their respective inhibitors is a clinical pitfall. For example, the potent ALK inhibitor Alectinib is not an effective ROS1 inhibitor. This distinction is critical for selecting the correct targeted therapy and avoiding treatment errors.

Next-gen ROS1 inhibitors like repotrectinib also inhibit the TRK protein, leading to a highly unusual side effect: severe, full-body withdrawal pain if the drug is held for surgery or radiation. The pain, which resolves within hours of restarting the pill, highlights a unique withdrawal phenomenon clinicians must anticipate.

The development of PARP-1 selective inhibitors like seriparib signals a shift in drug innovation. Instead of only chasing higher efficacy, these new agents aim for a more favorable toxicity profile (less GI toxicity, fewer dose discontinuations) to improve patient quality of life and treatment adherence.

For patients who achieve a deep response to a PARP inhibitor but struggle with persistent hematologic toxicity despite dose reductions, a practical clinical strategy is to switch to a different agent within the same class (e.g., from olaparib to rucaparib). This may offer a chance for improved tolerability while maintaining therapeutic benefit.

The distinct side effect profiles of pan-RAS inhibitors (rash, mucositis) and G12D-specific inhibitors (GI issues) are driving separate clinical strategies. The G12D drugs' better combinability with chemotherapy contrasts with pan-RAS agents, which may be better suited for monotherapy due to toxicity from blocking normal RAS.

While both Talatrectinib and Repotrectinib show impressive efficacy in ROS1-positive NSCLC, the choice between them can hinge on their side effect profiles. Talatrectinib demonstrates lower rates of TRK-related adverse events like dizziness, offering a key advantage in clinical practice.

While pan-RAS inhibitors like daraxoracib show broad efficacy irrespective of mutation, allele-specific agents may have fewer side effects and more predictable resistance patterns. This creates a clinical trade-off between immediate applicability and a more tailored, potentially better-tolerated long-term strategy.